Generation Bio Co.
GBIODelisted Feb 9, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001733294
Generation Bio Co. was delisted on Feb 9, 2026; its insiders filed their last Form 4 on Feb 9, 2026; 48 institutions reported holding it in 13F filings for Q4 2025, worth $24.5M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Generation Bio Co. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Generation Bio Co., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Atlas Venture Fund X, L.P. | 10% Owner | 0Indirect | Feb 9, 2026 | 1 |
| Atlas Venture Associates X, LLC | 10% Owner | 0Indirect | Feb 9, 2026 | 1 |
| Atlas Venture Associates X, L.P. | 10% Owner | 0Indirect | Feb 9, 2026 | 1 |
| Atlas Venture Opportunity Fund I, L.P. | 10% Owner | 0Indirect | Feb 9, 2026 | 1 |
| Atlas Venture Associates Opportunity I, L.P. | 10% Owner | 0Indirect | Feb 9, 2026 | 1 |
| Atlas Venture Associates Opportunity I, LLC | 10% Owner | 0Indirect | Feb 9, 2026 | 1 |
| Jonas Jeffrey M | Director | – | Feb 9, 2026 | 1 |
| Rowland Charles A Jr | Director | 0 | Feb 9, 2026 | 1 |
| Christensen Gustav | Director | 0 | Feb 9, 2026 | 1 |
| Quinn Anthony G. | Director | 0Indirect | Feb 9, 2026 | 1 |
| Rhodes Jason P | Director | 0Indirect | Feb 9, 2026 | 1 |
| Cooper Ronald Harold Wilfred | Director | 0 | Feb 9, 2026 | 1 |
| Stehman-Breen Catherine | Director | 0 | Feb 9, 2026 | 1 |
| McDonough Geoff | Director | 0Indirect | Feb 9, 2026 | 5 |
| Nicholson Donald William | Director | 0 | Feb 9, 2026 | 1 |
| Howze Yalonda | INTERIM CEO AND PRESIDENT | 0 | Feb 9, 2026 | 4 |
| Appelhans Dannielle | Director | 0Indirect | Feb 9, 2026 | 1 |
| Conway Kevin John | CHIEF FINANCIAL OFFICER | 0 | Feb 9, 2026 | 4 |
| Paone Antoinette | CHIEF OPERATING OFFICER | 3,658 | Oct 31, 2025 | 2 |
| Samayoa Phillip | CHIEF SCIENTIFIC OFFICER | 14,138 | Oct 31, 2025 | 2 |
| Stanton Matthew | CHIEF SCIENTIFIC OFFICER | 247,319 | Jan 10, 2025 | 0 |
| Norkunas Matthew | CHIEF FINANCIAL OFFICER | 57,348 | Jan 10, 2025 | 0 |
| Kerr Douglas | CHIEF MEDICAL OFFICER | 385,628 | Jan 31, 2024 | 0 |
| Zimmermann Tracy | CHIEF DEVELOPMENT OFFICER | 49,164 | Jan 31, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 14, 2025 (view filing) | Jan 10-13 | 4 days | Quinn Anthony G.Director | PPurchase | +210.8K | $0.964 | +$203.2K | +238.2%299.3K after | 2 lots |
| Jul 3, 2024 (view filing) | Jul 1 | 2 days | Paone AntoinetteCHIEF OPERATING OFFICER | SSale | −6.72K | $2.74 | −$18.4K | −32.7%13.8K after | |
| Jan 3, 2024 (view filing) | Jan 2 | 1 day | Samayoa PhillipCHIEF STRATEGY OFFICER | SSale | −2.44K | $1.62 | −$3.96K | −2.2%107.3K after | 10b5-1 |
| Jan 3, 2024 (view filing) | Jan 2 | 1 day | Paone AntoinetteCHIEF OPERATING OFFICER | SSale | −2.44K | $1.62 | −$3.96K | −29.6%5.83K after | 10b5-1 |
| Dec 11, 2023 (view filing) | Dec 8 | 3 days | Appelhans DannielleDirector | PPurchase | +637 | $1.82 | +$1.16K | +5.3%12.6K after | |
| Dec 11, 2023 (view filing) | Dec 8 | 3 days | Appelhans DannielleDirector | PPurchase | +7.36K | $1.79 | +$13.2K | New position7.36K after | |
| Dec 6, 2023 (view filing) | Dec 4 | 2 days | Appelhans DannielleDirector | PPurchase | +12.0K | $1.50 | +$18.0K | New position12.0K after | |
| Dec 5, 2023 (view filing) | Dec 1-4 | 4 days | Rowland Charles A JrDirector | PPurchase | +343.0K | $1.39 | +$477.8K | +178.8%534.8K after | 2 lots |
| Dec 5, 2023 (view filing) | Dec 1 | 4 days | Quinn Anthony G.Director | PPurchase | +88.5K | $1.41 | +$124.8K | New position88.5K after | |
| Dec 5, 2023 (view filing) | Dec 1 | 4 days | Nicholson Donald WilliamDirector | PPurchase | +100.0K | $1.44 | +$144.0K | +88.0%213.6K after | |
| Aug 25, 2023 (view filing) | Aug 23 | 2 days | Paone AntoinetteCHIEF OPERATING OFFICER | SSale | −3.12K | $4.93 | −$15.4K | −51.7%2.91K after | 10b5-1 |
| Jul 5, 2023 (view filing) | Jul 3 | 2 days | Samayoa PhillipCHIEF STRATEGY OFFICER | SSale | −3.12K | $5.29 | −$16.5K | −3.0%101.4K after | 10b5-1 |
| Apr 26, 2023 (view filing) | Apr 25 | 1 day | Paone AntoinetteCHIEF OPERATING OFFICER | SSale | −2.91K | $4.61 | −$13.4K | −100.0%0 after | 10b5-1 |
| Jan 27, 2023 (view filing) | Jan 26 | 1 day | Paone AntoinetteCHIEF OPERATING OFFICER | SSale | −2.69K | $5.56 | −$15.0K | −100.0%0 after | |
| Jan 11, 2023 (view filing) | Jan 10 | 1 day | Paone AntoinetteCHIEF OPERATING OFFICER | SSale | −1.86K | $4.57 | −$8.52K | −100.0%0 after | |
| Jan 10, 2023 (view filing) | Jan 9 | 1 day | Samayoa PhillipCHIEF STRATEGY OFFICER | SSale | −1.86K | $5.11 | −$9.53K | −1.9%95.8K after | |
| Oct 28, 2022 (view filing) | Oct 27 | 1 day | Paone AntoinetteCHIEF OPERATING OFFICER | SSale | −2.91K | $5.03 | −$14.7K | −100.0%0 after | |
| Sep 30, 2022 (view filing) | Sep 29 | 1 day | Paone AntoinetteCHIEF OPERATING OFFICER | SSale | −2.83K | $5.24 | −$14.8K | −100.0%0 after | |
| Sep 20, 2022 (view filing) | Sep 19 | 1 day | Rowland Charles A JrDirector | PPurchase | +15.8K | $5.26 | +$82.8K | +8.9%191.8K after | |
| Sep 19, 2022 (view filing) | Sep 15 | 4 days | Paone AntoinetteCHIEF OPERATING OFFICER | SSale | −4.61K | $5.32 | −$24.5K | −62.0%2.83K after | |
| Sep 19, 2022 (view filing) | Sep 15-16 | 4 days | Rowland Charles A JrDirector | PPurchase | +50.6K | $5.46 | +$276.2K | +40.4%176.0K after | 2 lots |
| Sep 15, 2022 (view filing) | Sep 13-14 | 2 days | Rowland Charles A JrDirector | PPurchase | +24.4K | $5.22 | +$127.4K | +24.1%125.4K after | 2 lots |
| Mar 11, 2022 (view filing) | Mar 9-10 | 2 days | Nicholson Donald WilliamDirector | PPurchase | +10.4K | $4.73 | +$49.3K | +10.1%113.6K after | 2 lots |
| Sep 29, 2021 (view filing)7:15 PM ET | Sep 27-29 | 2 days | Atlas Venture Associates X, LLC and 3 others10% Owner | SSale | −80.9K | $25.40 | −$2.06M | −100.0%0 after | 3 lots |
| Sep 29, 2021 (view filing)7:15 PM ET | Sep 27-29 | 2 days | Atlas Venture Associates X, LLC and 3 others10% Owner | SSale | −149 | $25.40 | −$3.78K | −19.7%608 after | 3 lots |
| Sep 29, 2021 (view filing) | Sep 27-29 | 2 days | Rhodes Jason PDirector | SSale | −81.1K | $25.40 | −$2.06M | −99.3%608 after | 6 lots |
| Sep 24, 2021 (view filing)8:59 PM ET | Sep 22-24 | 2 days | Atlas Venture Associates X, LLC and 3 others10% Owner | SSale | −134.7K | $26.02 | −$3.51M | −62.5%80.9K after | 4 lots |
| Sep 24, 2021 (view filing)8:59 PM ET | Sep 22-24 | 2 days | Atlas Venture Associates X, LLC and 3 others10% Owner | SSale | −251 | $26.01 | −$6.53K | −24.9%757 after | 3 lots |
| Sep 24, 2021 (view filing) | Sep 22-24 | 2 days | Rhodes Jason PDirector | SSale | −135.0K | $26.01 | −$3.51M | −99.4%757 after | 7 lots |
| Sep 16, 2021 (view filing) | Sep 14 | 2 days | Stanton MatthewCHIEF SCIENTIFIC OFFICER | SSale | −4.50K | $28.07 | −$126.3K | −2.2%198.2K after | |
| Sep 14, 2021 (view filing) | Sep 10 | 4 days | Stanton MatthewCHIEF SCIENTIFIC OFFICER | SSale | −3.00K | $25.97 | −$77.9K | −1.5%198.2K after | 2 lots |
| Aug 25, 2021 (view filing) | Aug 23 | 2 days | Stanton MatthewCHIEF SCIENTIFIC OFFICER | SSale | −1.50K | $25.04 | −$37.6K | −0.8%198.2K after | |
| Aug 11, 2021 (view filing) | Aug 10 | 1 day | Stanton MatthewCHIEF SCIENTIFIC OFFICER | SSale | −1.50K | $22.63 | −$33.9K | −0.8%198.2K after | 3 lots |
| Jul 14, 2021 (view filing) | Jul 12 | 2 days | Stanton MatthewCHIEF SCIENTIFIC OFFICER | SSale | −3.00K | $25.03 | −$75.1K | −1.5%198.2K after | 2 lots |
| Jul 12, 2021 (view filing) | Jul 8 | 4 days | Kerr DouglasCHIEF MEDICAL OFFICER | SSale | −3.52K | $25.20 | −$88.7K | −1.1%326.6K after | 2 lots |